Systems biology for identification of molecular networks in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 5, 2009, Pages 529-530

  Han, May H ^a   Steinman, L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NATALIZUMAB; OSTEOPONTIN; PROTEOME; RAS PROTEIN; RHO FACTOR; TRANSFER RNA; VERY LATE ACTIVATION ANTIGEN 4;

DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LYMPHOCYTE HOMING; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS;

HUMANS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; SYSTEMS BIOLOGY;

EID: 65349155780     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509103318     Document Type: Editorial

References (21)

1. Satoh JI Tabunoki H Yamamura T. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 2009; 15: 531-541.
2. Villoslada P, Steinman, L, Baranzini, S. Systems Biology and Its Application to the Understanding of Neurological Diseases. Annals of Neurology 2008 (in press).
3. Han MH Hwang SI Roy DB. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
4. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5: 575-581.
5. Lock C Hermans G Pedotti R. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
6. Chabas D Baranzini SE Mitchell D. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-1735.
7. Lassmann H Bruck W Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-1121
8. Fernald GH Knott S Pachner A. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007; 178: 5076-5085.
9. Miller DH Khan OA Sheremata WA. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
10. Polman CH O'Connor PW Havrdova E. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
11. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 2005; 4: 510-518.
12. Murugaiyan G Mittal A Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008; 181: 7480-7488.
13. Vogt MH Floris S Killestein J. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004; 155: 155-160.
14. Comabella M Pericot I Goertsches R. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158: 231-239.
15. Hur EM Youssef S Haws ME Zhang SY Sobel RA Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8: 74-83.
16. Youssef S Steinman L. At once harmful and beneficial: The dual properties of NF-kappaB. Nat Immunol 2006; 7: 901-902.
17. Singh RA Zhang JZ. Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol 2004; 173: 7299-7307.
18. Wu L Han DK. Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev Proteomics 2006; 3: 611-619.
19. Dunn SE Youssef S Goldstein MJ. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401-412.
20. Linker RA Lee DH Stangel M Gold R. Fumarates for the treatment of multiple sclerosis: Potential mechanisms of action and clinical studies. Expert Rev Neurother 2008; 8: 1683-1690.
21. Nobel D. The music of life: Biology beyond the genome. Oxford University Press, USA; 2006.